5 Amendments of Stelios KOULOGLOU related to 2016/2057(INI)
Amendment 2 #
Draft opinion
Paragraph 1
Paragraph 1
1. Recalls that the highest attainable standard of health is a fundamental right of every human being; Recalls that Sustainable Development Goal 3, with nine quantitative and four qualitative targets, clearly states that by 2030 everyone should have access to good mental and physical health throughout their lives; underlines that, each year, 100 million people fall into poverty because of health costs which are disproportionate to their incomes, and that, according to the WHO, over one third of the world’s population, with over 50 % in Africa, does not have access to medicines;
Amendment 14 #
Draft opinion
Paragraph 1 a (new)
Paragraph 1 a (new)
1a. Recalls that a high level of human health protection shall be ensured in the definition and implementation of all Union policies and activities, as stated by Article 168 of the TFEU;
Amendment 31 #
Draft opinion
Paragraph 2
Paragraph 2
2. Urges not to use free trade agreements with low- and middle-income countries (LMICs) to introduce TRIPS- plus intellectual property (IP) rules that extend monopoly protection and limit people's rights to health, and not to introduce new IP enforcement rules or investment protection to the detriment of access to medicines; calls, in this regard, on the Commission to safeguard the right of countries to regulate and preserve policy space in order to guarantee universal access to medicines; urges the Commission to ensure that trade agreements and policies do not undermine developing countries' strategic policies to guarantee people's right to health;
Amendment 51 #
Draft opinion
Paragraph 3 a (new)
Paragraph 3 a (new)
3a. Deplores that the current biomedical R&D system has proven, far from presenting incentives for research, to materialise in patent monopolies; compartmentalised and overlapping groups of multiple patents over single goods or technologies (thickets), lack of knowledge transfer and an obscure manipulation of the scientific method, all of which hinders innovation;
Amendment 57 #
Draft opinion
Paragraph 4
Paragraph 4
4. Stresses that, without transparency of research and development costs to originator companies and information on the actual prices paid for medicines across the EU, any discussion on fair medicine prices remains impossible; recalls the Commission’'s commitment to greater transparency of EU positions, specific legal proposals, and negotiating texts in the TTIP negotiationall trade agreements; De-linkage in biomedical R&D shall imply separating research and development costs from the final price of the medicine, thus broadly facilitating access and generic production in the developing world; calls in this regard for enhancing instruments such as price incentives for open source medical research, patent pools, socially responsible licences, imposing strict conditions on the use and exploitation of public research by private corporations to assure a return for public interest, open access to scientific research developed and financed with public funds and transparency on trial results;